Fennec Pharmaceuticals Posts Strong Second Quarter 2025 Results
~ Achieved Total Net Revenues of $9.7 Million in Q2 2025 ~
~ Experienced Double-Digit Growth in New Accounts and Strong Demand for PEDMARK ~
~ Launching PEDMARQSI in Additional EU Countries ~
~ Anticipated Results from Japan's Clinical Trials in Late 2025 ~
RESEARCH TRIANGLE PARK, N.C. -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX:FRX), a specialized pharmaceutical company dedicated to improving patient outcomes, has reported its financial results for the second quarter of 2025, showcasing considerable growth and innovation.
“Our performance in Q2 reflects the successful implementation of our revamped strategy, with revenues soaring 33% compared to last year,” expressed Jeff Hackman, CEO of Fennec Pharmaceuticals. “We’re witnessing remarkable demand for PEDMARK® as it gains traction among both community practices and academic institutions. Our strategy, aimed at increasing awareness and enhancing patient support, is clearly paying off.”
Business Highlights
Continued Expansion in Key Accounts
Fennec’s innovative segmentation approach in targeting accounts has significantly elevated both new and existing customer engagement. Growth was particularly strong within large community practices and academic centers.
Inclusion in National Oncology Group Formulary
A prominent national oncology group has added PEDMARK® to its formulary for patients under 40, marking a pivotal step in broader acceptance and integration within the community oncology setting. This decision signifies a growing recognition of the importance of protecting younger patients from cisplatin-induced hearing loss.
Positive Quality Intervention Issued for PEDMARK
NCODA issued a Positive Quality Intervention (PQI) for PEDMARK®, offering vital clinical data and guidance for healthcare professionals managing pediatric patients at risk of ototoxicity.
Growth in Enrollment for Fennec HEARS™ Program
The patient support program has seen an increase in enrollment, showcasing our commitment to improving patient experiences through enhanced service offerings and streamlined nursing support.
Upcoming Events
NASDAQ Closing Bell Ceremony in September
Fennec’s leadership team will join patients and their families to ring the NASDAQ closing bell, a symbol of our commitment to community involvement and awareness.
Presentation at H.C. Wainwright Global Investment Conference
Management is scheduled to present insights and updates at this prestigious conference, further solidifying our position within the investment community.
Financial Overview for Q2 2025
In the second quarter, Fennec recorded net product sales of approximately $9.7 million, a notable increase from $7.3 million in the same period last year due to an intensified focus on pediatric populations.
Key Financial Details
- Selling and Marketing Expenses: $4.4 million, a slight decrease from $4.6 million last year, reflecting optimized spending on effective marketing strategies.
- General and Administrative Expenses: $7.0 million, consistent with previous year, primarily attributed to increased IP expenses.
- Cash Position: Ended the quarter with $18.7 million in cash, adjusted for projected operational expenses typical for the season.
Recent Developments for PEDMARK®
PEDMARK has emerged as a breakthrough in preventing cisplatin-induced hearing loss for pediatric patients. With over 500,000 cancer diagnoses annually within the U.S. involving platinum-based treatments, the need for preventive therapies like PEDMARK is critical.
PEDMARK® offers a unique formulation that is both FDA approved and respected by health authorities worldwide, indicating a robust future for patient care innovation. As clinical results continue to affirm its efficacy, Fennec Pharmaceuticals is set to strengthen its footprint in oncological care.
Frequently Asked Questions
What are the key financial results for Fennec Pharmaceuticals in Q2 2025?
The key result includes total net revenues of $9.7 million, representing a 33% increase from Q2 of 2024.
What progress has Fennec made in expanding PEDMARK?
Fennec has added new accounts in large community practices and increased acknowledgment of its impact in pediatric oncology.
What events are coming up for Fennec Pharmaceuticals?
Fennec will participate in the NASDAQ closing bell ceremony and present at the H.C. Wainwright Global Investment Conference.
Has PEDMARK received any endorsements?
Yes, PEDMARK is endorsed by prestigious oncology groups and has been recommended for use in the adolescent and young adult population.
What is the future outlook for Fennec Pharmaceuticals?
With ongoing growth and expansion strategies, coupled with strong demand for PEDMARK, the outlook is robust for Fennec Pharmaceuticals in the coming years.
